
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuroimage Clin</journal-id><journal-id journal-id-type="iso-abbrev">Neuroimage Clin</journal-id><journal-title-group><journal-title>NeuroImage : Clinical</journal-title></journal-title-group><issn pub-type="epub">2213-1582</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32950904</article-id><article-id pub-id-type="pmc">7502564</article-id><article-id pub-id-type="publisher-id">S2213-1582(20)30248-5</article-id><article-id pub-id-type="doi">10.1016/j.nicl.2020.102411</article-id><article-id pub-id-type="publisher-id">102411</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Mart&#x000ed;nez-Heras</surname><given-names>Eloy</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Solana</surname><given-names>Elisabeth</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Prados</surname><given-names>Ferran</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="af015" ref-type="aff">c</xref><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Andorr&#x000e0;</surname><given-names>Mag&#x000ed;</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Solanes</surname><given-names>Aleix</given-names></name><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>L&#x000f3;pez-Soley</surname><given-names>Elisabet</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Montejo</surname><given-names>Carmen</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au040"><name><surname>Pulido-Valdeolivas</surname><given-names>Irene</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au045"><name><surname>Alba-Arbalat</surname><given-names>Salut</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au050"><name><surname>Sola-Valls</surname><given-names>Nuria</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au055"><name><surname>Sep&#x000fa;lveda</surname><given-names>Maria</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au060"><name><surname>Blanco</surname><given-names>Yolanda</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au065"><name><surname>Saiz</surname><given-names>Albert</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au070"><name><surname>Radua</surname><given-names>Joaquim</given-names></name><email>radua@clinic.cat</email><xref rid="af025" ref-type="aff">e</xref><xref rid="af030" ref-type="aff">f</xref><xref rid="af035" ref-type="aff">g</xref><xref rid="fn2" ref-type="fn">2</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au075"><name><surname>Llufriu</surname><given-names>Sara</given-names></name><email>sllufriu@clinic.cat</email><xref rid="af005" ref-type="aff">a</xref><xref rid="fn2" ref-type="fn">2</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d&#x02019;Investigacions Biom&#x000e8;diques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain</aff><aff id="af010"><label>b</label>E-health Centre, Universitat Oberta de Catalunya, Barcelona, Spain</aff><aff id="af015"><label>c</label>Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK</aff><aff id="af020"><label>d</label>NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK</aff><aff id="af025"><label>e</label>Imaging of Mood- and Anxiety-related Disorders (IMARD) Group, IDIBAPS and CIBERSAM, Barcelona, Spain</aff><aff id="af030"><label>f</label>Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden</aff><aff id="af035"><label>g</label>Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding authors at: Hospital Clinic Barcelona, Calle Villarroel 170, Barcelona, CP 08036, Spain. Imaging of Mood- and Anxiety-Related Disorders (IMARD) group, Institut d'Investigacions Biom&#x000e8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. <email>radua@clinic.cat</email><email>sllufriu@clinic.cat</email></corresp><fn id="fn1"><label>1</label><p id="np005">These authors contributed equally.</p></fn><fn id="fn2"><label>2</label><p id="np010">Contributed equally corresponding authors.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>9</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>09</day><month>9</month><year>2020</year></pub-date><volume>28</volume><elocation-id>102411</elocation-id><history><date date-type="received"><day>22</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>24</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">Macroscopic and microscopic diffusion properties discriminate between MS lesion types.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">The number and volume of lesions with larger diffusion changes are associated with worse clinical outcomes.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">Diffusion MRI provides useful information of the pathological heterogeneity in plaques.</p></list-item></list></p></abstract><abstract id="ab010"><p>Diffusion magnetic resonance imaging can reveal quantitative information about the tissue changes in multiple sclerosis. The recently developed multi-compartment spherical mean technique can map different microscopic properties based only on local diffusion signals, and it may provide specific information on the underlying microstructural modifications that arise in multiple sclerosis. Given that the lesions in multiple sclerosis may reflect different degrees of damage, we hypothesized that quantitative diffusion maps may help characterize the severity of lesions &#x0201c;<italic>in vivo</italic>&#x0201d; and correlate these to an individual&#x02019;s clinical profile. We evaluated this in a cohort of 59 multiple sclerosis patients (62% female, mean age 44.7&#x000a0;years), for whom demographic and disease information was obtained, and who underwent a comprehensive physical and cognitive evaluation. The magnetic resonance imaging protocol included conventional sequences to define focal lesions, and multi-shell diffusion imaging was used with b-values of 1000, 2000 and 3000&#x000a0;s/mm<sup>2</sup> in 180 encoding directions. Quantitative diffusion properties on a macro- and micro-scale were used to discriminate distinct types of lesions through a k-means clustering algorithm, and the number and volume of those lesion types were correlated with parameters of the disease. The combination of diffusion tensor imaging metrics (fractional anisotropy and radial diffusivity) and multi-compartment spherical mean technique values (microscopic fractional anisotropy and intra-neurite volume fraction) differentiated two type of lesions, with a prediction strength of 0.931. The B-type lesions had larger diffusion changes compared to the A-type lesions, irrespective of their location (P&#x000a0;&#x0003c;&#x000a0;0.001). The number of A and B type lesions was similar, although in juxtacortical areas B-type lesions predominated (60%, P&#x000a0;&#x0003c;&#x000a0;0.001). Also, the percentage of B-type lesion volume was higher (64%, P&#x000a0;&#x0003c;&#x000a0;0.001), indicating that these lesions were larger. The number and volume of B-type lesions was related to the severity of disease evolution, clinical disability and cognitive decline (P&#x000a0;=&#x000a0;0.004, Bonferroni correction). Specifically, more and larger B-type lesions were correlated with a worse Multiple Sclerosis Severity Score, cerebellar function and cognitive performance. Thus, by combining several microscopic and macroscopic diffusion properties, the severity of damage within focal lesions can be characterized, further contributing to our understanding of the mechanisms that drive disease evolution. Accordingly, the classification of lesion types has the potential to permit more specific and better-targeted treatment of patients with multiple sclerosis.</p></abstract><kwd-group id="kg005"><title>Abbreviations</title><kwd>T1 3D-MPRAGE, 3D-Magnetization Prepared Rapid Acquisition Gradient Echo</kwd><kwd>3D-T2, 3D-T2 fluid-attenuated inversion recovery</kwd><kwd>AD, Axial diffusivity</kwd><kwd>BRB-N, Brief Repeatable Battery of neuropsychological tests</kwd><kwd>DTI, Diffusion tensor imaging</kwd><kwd>DWIs, Diffusion-weighted images</kwd><kwd>EDSS, Expanded disability status scale</kwd><kwd><italic>v</italic><sub>MD</sub>, Extra-neurite microscopic mean diffusivity</kwd><kwd><italic>v</italic><sub>AD</sub>, Extra-neurite transverse microscopic diffusivity</kwd><kwd>FA, Fractional anisotropy</kwd><kwd>&#x00192;<sub>in</sub>, Intra-neurite volume fraction</kwd><kwd>&#x003bb;<sub>diff</sub>, Intrinsic diffusivity</kwd><kwd>MC-SMT, Multi-compartment spherical mean technique</kwd><kwd>MD, Mean diffusivity</kwd><kwd>MS, Multiple sclerosis</kwd><kwd>MSSS, Multiple sclerosis severity score</kwd><kwd>NAWM, Normal-appearing white matter</kwd><kwd>RD, radial diffusivity</kwd><kwd>RR, Relapsing remitting</kwd><kwd>SP, Secondary progressive</kwd></kwd-group><kwd-group id="kg010"><title>Keywords</title><kwd>MRI</kwd><kwd>Diffusion magnetic resonance imaging</kwd><kwd>K-means clustering algorithm</kwd><kwd>MS lesion types</kwd><kwd>Multiple Sclerosis</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0020">Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) that is characterised by the presence of focal lesions, and damage to the normal-appearing white matter (NAWM) and the grey matter (<xref rid="b0115" ref-type="bibr">Lassmann et al., 2007</xref>). There is substantial heterogeneity in the pathological changes among MS lesions, with different patterns of demyelination (<xref rid="b0120" ref-type="bibr">Lucchinetti et al., 2000</xref>) and a variable degree of neuroaxonal damage having been described (<xref rid="b0125" ref-type="bibr">Ludwin, 2006</xref>). In addition, while active plaques are most often found at early disease stages, smoldering, inactive and shadow plaques subsequently predominate. Chronic active lesions are associated with a more aggressive disease evolution (<xref rid="b0005" ref-type="bibr">Absinta et al., 2019</xref>, <xref rid="b0120" ref-type="bibr">Lucchinetti et al., 2000</xref>) and indeed, differences in the severity of demyelination, remyelination and neuroaxonal damage could explain why some patients recover completely from relapses yet in others, their disability deteriorates more rapidly.</p><p id="p0025">The changes in lesions and in the NAWM can be visualised through conventional magnetic resonance imaging (MRI), yet they are poorly associated with the clinical phenotype and physical disability (<xref rid="b0015" ref-type="bibr">Barkhof, 2002</xref>), partly reflecting the failure to characterise the pathological nature of tissue injury in MS. However, diffusion MRI-based techniques can reveal quantitative and more specific information about the mechanisms associated with tissue changes (<xref rid="b0155" ref-type="bibr">Rocca et al., 2015</xref>). Macroscopic diffusion properties have been studied extensively in MS lesions using diffusion tensor imaging (DTI) features, such as the reduction in fractional anisotropy (FA) relative to the NAWM. Unfortunately, DTI findings are strongly influenced by a complex intravoxel fibre architecture, which limits the ability to accurately estimate the different pathophysiological features of the disease (<xref rid="b0165" ref-type="bibr">Rovaris et al., 2005</xref>, <xref rid="b0050" ref-type="bibr">Filippi and Rocca, 2011</xref>).</p><p id="p0030">Recently, several microstructure imaging techniques have been proposed to compute distinct signal contribution patterns with the aim to provide greater sensitivity and specificity toward the underlying damage mechanisms (<xref rid="b0140" ref-type="bibr">Novikov et al., 2019</xref>). Several mathematical representations from biophysical models have been exploited to understand the contribution of restricted intracellular diffusion components (<xref rid="b0100" ref-type="bibr">Kroenke et al., 2004</xref>). The estimation of local diffusion properties based on multi-compartment spherical mean technique (MC-SMT) has successfully decomposed the distinct signal components into microscopic tissue features (<xref rid="b0095" ref-type="bibr">Kaden et al., 2016</xref>). Thus, this approach is only sensitive to fibre composition, whereas DTI metrics depend on both intravoxel fibre orientation, distribution and microstructure (<xref rid="b0130" ref-type="bibr">Mollink et al., 2017</xref>, <xref rid="b0085" ref-type="bibr">Jones et al., 2018</xref>). The MC-SMT model computes a multi-compartment domain, encompassing extra-axonal and intra-axonal water diffusion spaces, and microscopic diffusion tensor maps to estimate distinct local tissue properties (<xref rid="b0095" ref-type="bibr">Kaden et al., 2016</xref>). In MS, MC-SMT seems to be able to distinguish chronic black-holes and thus, lesions with greater tissue damage from hyperintense T2 lesions (<xref rid="b0010" ref-type="bibr">Bagnato et al., 2019</xref>, <xref rid="b0030" ref-type="bibr">Bonet-Carne et al., 2019</xref>), and this approach can detect reductions in the apparent axon volume fraction in the spinal cord (SC) (<xref rid="b0035" ref-type="bibr">By et al., 2018</xref>). Therefore, SMT-derived tissue features could be used as biomarkers to quantify the heterogeneous mechanisms involved in MS lesion pathogenesis <italic>in vivo</italic>.</p><p id="p0035">Considering that MS lesions can display different degrees of damage, we hypothesized that the combination of several diffusion properties may be useful to characterize the severity of the changes in these lesions. Thus, measuring such variability could provide insights into the progression of disability and cognitive decline in patients with MS. Accordingly, the main aims of this study were to characterise MS lesions through macroscopic and microscopic diffusion information, and classify them in terms of the degree of damage, also determining the clinical relevance of the different types of lesions.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Participants</title><p id="p0040">We prospectively recruited a cohort of 59 MS patients at the MS Unit of the Hospital Clinic of Barcelona, 53 relapsing remitting (RR) and 6 secondary progressive (SP) patients according to 2010 McDonald criteria (<xref rid="b0145" ref-type="bibr">Polman et al., 2011</xref>). Patients had to be relapse-free and free of corticosteroids in the month prior to testing. The Ethics Committee of the Hospital Clinic of Barcelona approved the study, and all participants provided their signed informed consent.</p><p id="p0045">Demographic and clinical data were obtained from each participant, which included their score on the Expanded Disability Status Scale (EDSS) and its sub-scores for pyramidal, brainstem and cerebellum function (<xref rid="b0105" ref-type="bibr">Kurtzke, 1983</xref>, <xref rid="b0170" ref-type="bibr">Roxburgh et al., 2005</xref>). Their Multiple Sclerosis Severity Score (MSSS, <xref rid="b0170" ref-type="bibr">Roxburgh et al., 2005</xref>) was also obtained and a cognitive assessment was performed using the Brief Repeatable Battery of neuropsychological tests (BRB-N, <xref rid="b0150" ref-type="bibr">Rao et al., 1991</xref>). All raw values were transformed into z-scores according to published Spanish normative data (<xref rid="b0175" ref-type="bibr">Sepulcre et al., 2006</xref>). The use of moderate-efficacy (interferon beta, glatiramer acetate, teriflunomide and dimethylfumarate) or high-efficacy (fingolimod, natalizumab, rituximab, ocrelizumab or cladribine) disease modifying therapies was registered.</p></sec><sec id="s0020"><label>2.2</label><title>Magnetic resonance imaging: Acquisition and processing</title><sec id="s0025"><label>2.2.1</label><title>Structural and diffusion magnetic resonance acquisition</title><p id="p0050">MR images were acquired on a SIEMENS Magnetom Prisma<sup>fit</sup> 3&#x000a0;T scanner with a 64-channel phased-array head/neck coil, and they included 3D-Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE), 3D-T2 fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted images (DWIs). Individual T1 3D-MPRAGE images had the following acquisition parameters: TR&#x000a0;=&#x000a0;1800&#x000a0;ms; TE&#x000a0;=&#x000a0;3.01&#x000a0;ms; TI&#x000a0;=&#x000a0;900&#x000a0;ms; 240 sagittal slices with 0.94&#x000a0;mm isotropic voxel size and a 256&#x000a0;&#x000d7;&#x000a0;256 matrix size. The 3D-T2 FLAIR sequence parameters were: TR&#x000a0;=&#x000a0;5000&#x000a0;ms; TE&#x000a0;=&#x000a0;379&#x000a0;ms; TI&#x000a0;=&#x000a0;1800&#x000a0;ms; 208 sagittal slices with 0.94&#x000a0;mm isotropic voxel size and a 256&#x000a0;&#x000d7;&#x000a0;256 matrix size. Multi-shell DWIs were acquired with: TR&#x000a0;=&#x000a0;5400&#x000a0;ms; TE&#x000a0;=&#x000a0;113&#x000a0;ms; parallel acceleration factor&#x000a0;=&#x000a0;4; phase partial Fourier&#x000a0;=&#x000a0;6/8; 100 contiguous axial slices at 1.5&#x000a0;mm isotropic voxel dimension; a 150&#x000a0;&#x000d7;&#x000a0;150 matrix size; b-values&#x000a0;=&#x000a0;1000, 2000 and 3000&#x000a0;s/mm<sup>2</sup> along 180 diffusion encoding directions; and 5b&#x000a0;=&#x000a0;0 images. In addition, field map images were generated to estimate and correct susceptibility artifacts caused by field inhomogeneities (TE 1/TE 2&#x000a0;=&#x000a0;4.92/7.38&#x000a0;ms, with the same slice prescription, slice thickness and field of view as the multi-shell DWIs).</p></sec><sec id="s0030"><label>2.2.2</label><title>Delineation mask and topography of MS lesions</title><p id="p0055">MS lesions were manually delineated on the T1 3D-MPRAGE image, supported by a co-registered FLAIR image, using JIM software (Jim version 6.0 Xinapse System, <ext-link ext-link-type="uri" xlink:href="http://www.xinapse.com/" id="ir005"><underline>http://www.xinapse.com/</underline></ext-link>). We characterised each lesion independently through its cluster size and defined their location automatically. We established the lesions in which&#x000a0;&#x0003e;&#x000a0;5% of their volume was in direct contact with the lateral ventricles as &#x0201c;periventricular lesions&#x0201d;, lesions with&#x000a0;&#x0003e;&#x000a0;20% of their volume touching or within the cortex as &#x0201c;juxtacortical lesions&#x0201d;, and brainstem or cerebellar lesions as &#x0201c;infratentorial lesions&#x0201d; if &#x0003e;50% of their volume was placed in the brainstem or cerebellum. Finally, we considered the remaining lesions as &#x0201c;lesions located elsewhere in the deep WM&#x0201d; (<xref rid="b0070" ref-type="bibr">Griffanti et al., 2018</xref>). Lesions smaller than 27&#x000a0;mm<sup>3</sup> were excluded from the analysis (<xref rid="b0045" ref-type="bibr">Filippi et al., 2019</xref>).</p></sec><sec id="s0035"><label>2.2.3</label><title>Processing multi-shell diffusion MRI data</title><p id="p0060">The diffusion imaging data was preprocessed using a combination of FSL and MRtrix software (<xref rid="b0195" ref-type="bibr">Tournier et al., 2019</xref>). The low b-value was used to compute DTI metrics with FSL&#x02019;s dtifit command by linear least-squares fitting method (<xref rid="b0020" ref-type="bibr">Basser et al., 1994</xref>) and all the diffusion shells were employed to map the microstructural diffusivity (<xref rid="b0095" ref-type="bibr">Kaden et al., 2016</xref>). Afterwards, we applied an inverse transformation matrix using boundary-based registration to place MS lesions into the diffusion space (<xref rid="b0065" ref-type="bibr">Greve and Fischl, 2009</xref>). For each patient, the following measures were assessed for each individual MS lesion, and in the global NAWM: Location (periventricular, juxtacortical, infratentorial or deep WM); lesion volume; DTI-derived metrics (FA, mean diffusivity: MD, radial diffusivity: RD and axial diffusivity: AD); SMT microscopic diffusion coefficients (&#x000b5;FA, &#x000b5;MD, &#x000b5;RD and &#x000b5;AD); and multi-compartment SMT microscopic diffusion coefficients (intra-neurite volume fraction: &#x00192;<sub>in</sub><sub>,</sub> intrinsic diffusivity: &#x003bb;<sub>diff</sub><sub>,</sub> extra-neurite transverse microscopic diffusivity: <italic>v</italic><sub>AD</sub> and extra-neurite microscopic mean diffusivity: <italic>v</italic><sub>MD</sub>). The macroscopic and microscopic diffusion properties were selected to perform k-means cluster analysis to further extract the specific diffusion indices able to classify MS lesion types.</p></sec></sec><sec id="s0040"><label>2.3</label><title>Statistical analysis</title><sec id="s0045"><label>2.3.1</label><title>Data-driven clustering of MS lesion types</title><p id="p0065">We based the classification of MS lesions on diffusion imaging. We want to highlight here that clustering techniques may create artificial groups of data that may not be replicated in new data. To minimise this possibility, we only considered those sets of diffusion MRI measurements that led to clusters that were independently and consistently replicated in new data for periventricular, juxtacortical, brainstem, cerebellar and deep WM MS lesions, as defined by a prediction strength&#x000a0;&#x0003e;&#x000a0;0.8 (<xref rid="b0185" ref-type="bibr">Tibshirani and Walther, 2005</xref>). The &#x0201c;prediction strength&#x0201d; is a parameter proposed by Tibshirani and Walther that assesses how well the clustering obtained from one random half of the overall sample of lesions coincides with the clustering obtained from the other half of the sample. Specifically, for each set of diffusion tensor metrics and microscopic diffusion coefficients, we applied a standard k-means algorithm with k&#x000a0;=&#x000a0;2 (i.e.: clustering the data into 2 groups) and performing a separate centroid-based classification for two random halves of the MS lesions, thereafter calculating the prediction strength. We are aware that there might be more than two types of lesions but for simplicity, we decided to only explore the two-type scenario - we understood that should there be three or more types of lesions, they might very well group as two main types. To avoid spurious results related to unfortunate divisions of the overall sample of lesions into two sets, we repeated this process 500 times and each time, the overall sample of lesions was divided randomly into two parts and the prediction strength was assessed. Subsequently, we averaged the corresponding 500 estimates of the prediction strength. Finally, to evaluate the significance of the prediction strength, we repeated these calculations after randomly assigning the diffusion characteristics of each lesion to other different lesions in order to create the distribution of prediction strengths under the null hypothesis (i.e.: that diffusion characteristics are not clustered). The resulting null distribution showed which prediction strengths could be expected by chance and thus, they allowed us to estimate the <italic>p</italic>-value.</p></sec><sec id="s0050"><label>2.3.2</label><title>Relationships between clustering and clinical variables</title><p id="p0070">Application of the selected clustering recognised two types of MS lesions, type A and B. We assessed whether the overall number or the volume of each type of lesion was correlated with the variables of disability. To do that, we fitted linear models with the clinical disability as the dependent variable, and the independent variables composed by the number or volume of each type of lesions, age and gender. Given that the residuals of some numeric variables may not follow a normal distribution, we found the statistical significance using the Freedman Lane permutation procedure, a common permutation test in neuroimaging studies due to its robustness to gross deviations of normality (<xref rid="b0205" ref-type="bibr">Winkler et al., 2014</xref>). For binary variables of disability, we fitted logistic linear models, in which again the dependent variable was the variable of disability, and the independent variables were the number or volume of lesion types, age and gender. For the sake of comprehensiveness, we reassessed the correlations that proved to be statistically significant, on this occasion performing the analysis separately for the MS lesions at each brain location.</p><p id="p0075">All the statistical analyses were carried out using the &#x0201c;fpc&#x0201d; (flexible procedures for clustering) package: <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/fpc/index.html" id="ir010"><underline>https://cran.r-project.org/web/packages/fpc/index.html</underline></ext-link>, implemented in the R platform (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/" id="ir015"><underline>https://www.r-project.org/</underline></ext-link>).</p></sec></sec></sec><sec id="s0055"><label>3</label><title>Results</title><p id="p0080">Clinical, demographic and cognitive data was collected from the 59 MS patients included in the study (as summarised in <xref rid="t0005" ref-type="table">Table 1</xref>), and the cohort had a mean age of 44.7 (&#x000b1;9.3) and 12.8 (&#x000b1;9.16) years of disease duration. Most patients were diagnosed with the RRMS form of the disease (90%).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Demographic, clinical and cognitive data of the included participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Multiple sclerosis patients<break/>n&#x000a0;=&#x000a0;59</th></tr></thead><tbody><tr><td>Age, years</td><td>44.7 (9.3)</td></tr><tr><td>Female, n (%)</td><td>37 (63)</td></tr><tr><td>MS type, n (%)<break/>Relapsing-remitting<break/>Secondary progressive</td><td><break/>53 (90%)<break/>6 (10%)</td></tr><tr><td>Disease modified treatment, n (%):<break/>Moderate-intensity therapy<break/>High-intensity therapy</td><td><break/>40 (77)<break/>12 (23)</td></tr><tr><td>Disease duration, years</td><td>12.8 (9.16)</td></tr><tr><td>EDSS score, median (range)</td><td>2.0 (0.0&#x02013;7.5)</td></tr><tr><td>Cerebellar FS, median (range)</td><td>0 (0&#x02013;4)</td></tr><tr><td>Pyramidal FS, median (range)</td><td>1 (0&#x02013;5)</td></tr><tr><td>Brainstem FS, median (range)</td><td>0 (0&#x02013;3)</td></tr><tr><td>MSSS, median (range)</td><td>2.28 (0.13&#x02013;8.55)</td></tr><tr><td>Global cognitive z-score</td><td>&#x02212;0.707 (1.011)</td></tr><tr><td>Visual memory z-score</td><td>&#x02212;0.429 (1.071)</td></tr><tr><td>Verbal memory z-score</td><td>&#x02212;1.045 (1.559)</td></tr><tr><td>Attention z-score</td><td>&#x02212;0.492 (1.371)</td></tr><tr><td>Fluency z-score</td><td>&#x02212;0.770 (1.125)</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are given as the mean (standard deviation), except if defined otherwise. EDSS&#x000a0;=&#x000a0;Expanded Disability Status Scale; FS&#x000a0;=&#x000a0;Functional System; MSSS&#x000a0;=&#x000a0;Multiple Sclerosis Severity Score.</p></fn></table-wrap-foot></table-wrap></p><sec id="s0060"><label>3.1</label><title>Characterization and classification of the MS lesions based on their diffusion properties</title><p id="p0085">We analysed 1,236 lesions in total, with a mean brain lesion volume of 11.37 (&#x000b1;15.30) cm<sup>3</sup>. We computed the mean DTI values and the microscopic properties of all lesions, both globally and at the distinct locations, as well as in the NAWM (<xref rid="t0010" ref-type="table">Table 2</xref>). These diffusion imaging properties were weakly correlated, and we discarded the &#x003bc;AD and AD measures given their small variation in the lesions (38% of the values corresponded to the maximum value of this measure). Two sets of diffusion MRI indices at macro- and micro-scale were computed to identify different MS lesion profiles, the clustering of which showed prediction strengths&#x0003e;0.8, irrespective of the lesion localization. The first set were distinguished on the basis of the parameters FA, RD, &#x003bc;FA and &#x00192;<sub>in</sub> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>), while the second set was defined by the same parameters in the same directions, except that &#x003bc;FA was replaced by &#x003bc;RD (which was higher in B-type lesions). The groups of lesions defined by the two clusters were 99% identical and as such, we decided to limit the study to the first cluster as this had a slightly higher prediction strength (0.931).<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Description of diffusion properties in MS lesions and normal-appearing white matter.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="6">MS lesions</th><th>NAWM</th></tr><tr><th/><th>Whole brain</th><th>Periventricular</th><th>Juxtacortical</th><th>Brainstem</th><th>Cerebellum</th><th>Deep WM</th><th/></tr></thead><tbody><tr><td>Total number of lesions analysed</td><td>1236</td><td>357</td><td>343</td><td>44</td><td>60</td><td>432</td><td>&#x02013;</td></tr><tr><td>Mean lesion volume [cm<sup>3</sup>]</td><td>11.37 (15.30)</td><td>9.75 (14.90)</td><td>0.82 (0.59)</td><td>0.20 (0.20)</td><td>0.47 (1.14)</td><td>1.54 (5.02)</td><td>&#x02013;</td></tr><tr><td colspan="7">DTI-derived tensor metrics:</td><td/></tr><tr><td>FA</td><td>0.32 (0.11)</td><td>0.31 (0.12)</td><td>0.27 (0.10)</td><td>0.36 (0.08)</td><td>0.36 (0.12)</td><td>0.36 (0.11)</td><td>0.36 (0.04)</td></tr><tr><td>MD**</td><td>0.57 (0.09)</td><td>0.60 (0.08)</td><td>0.62 (0.08)</td><td>0.43 (0.07)</td><td>0.48 (0.08)</td><td>0.54 (0.08)</td><td>0.46 (0.03)</td></tr><tr><td>RD**</td><td>0.47 (0.10)</td><td>0.49 (0.09)</td><td>0.53 (0.09)</td><td>0.34 (0.07)</td><td>0.38 (0.09)</td><td>0.43 (0.09)</td><td>0.37 (0.04)</td></tr><tr><td>AD**</td><td>0.77 (0.11)</td><td>0.80 (0.10)</td><td>0.79 (0.11)</td><td>0.61 (0.10)</td><td>0.67 (0.09)</td><td>0.76 (0.11)</td><td>0.64 (0.03)</td></tr><tr><td colspan="7">SMT microscopic diffusion tensor:</td><td/></tr><tr><td>&#x003bc;FA</td><td>0.83 (0.09)</td><td>0.78 (0.12)</td><td>0.82 (0.06)</td><td>0.93 (0.04)</td><td>0.91 (0.03)</td><td>0.87 (0.07)</td><td>0.90 (0.03)</td></tr><tr><td>&#x003bc;MD**</td><td>1.30 (0.19)</td><td>1.40 (0.23)</td><td>1.30 (0.13)</td><td>1.09 (0.08)</td><td>1.13 (0.08)</td><td>1.23 (0.14)</td><td>1.04 (0.06)</td></tr><tr><td>&#x003bc;RD**</td><td>0.44 (0.26)</td><td>0.60 (0.33)</td><td>0.47 (0.16)</td><td>0.18 (0.09)</td><td>0.23 (0.09)</td><td>0.35 (0.18)</td><td>0.23 (0.07)</td></tr><tr><td>&#x003bc;AD**</td><td>2.99 (0.11)</td><td>3.02 (0.07)</td><td>2.97 (0.14)</td><td>2.92 (0.12)</td><td>2.92 (0.12)</td><td>3.01 (0.09)</td><td>2.66 (0.07)</td></tr><tr><td colspan="7">Multi-compartment microscopic diffusion coefficients:</td><td/></tr><tr><td>&#x00192;<sub>in</sub></td><td>0.34 (0.13)</td><td>0.29 (0.10)</td><td>0.28 (0.09)</td><td>0.56 (0.02)</td><td>0.47 (0.15)</td><td>0.38 (0.13)</td><td>0.50 (0.06)</td></tr><tr><td>&#x003bb;<sub>diff</sub>**</td><td>2.09 (0.35)</td><td>2.19 (0.32)</td><td>1.93 (0.31)</td><td>2.25 (0.40)</td><td>2.10 (0.48)</td><td>2.11 (0.34)</td><td>2.02 (0.16)</td></tr><tr><td><italic>V</italic><sub>AD</sub>**</td><td>1.35 (0.32)</td><td>1.54 (0.33)</td><td>1.40 (0.23)</td><td>0.92 (0.30)</td><td>1.10 (0.21)</td><td>1.27 (0.28)</td><td>0.91 (0.13)</td></tr><tr><td><italic>V</italic><sub>MD</sub>**</td><td>1.60 (0.28)</td><td>1.75 (0.30)</td><td>1.60 (0.23)</td><td>1.36 (0.18)</td><td>1.40 (0.20)</td><td>1.55 (0.24)</td><td>1.28 (0.10)</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are given as the mean (standard deviation). The numbers are the lesion counts in the first row and the mean metrics across the lesions in the other rows. FA&#x000a0;=&#x000a0;Fractional anisotropy; MD&#x000a0;=&#x000a0;Mean diffusivity; RD&#x000a0;=&#x000a0;Radial diffusivity; AD&#x000a0;=&#x000a0;Axial diffusivity; &#x00192;<sub>in</sub>&#x000a0;=&#x000a0;intra-neurite volume fraction; &#x003bb;<sub>diff</sub>&#x000a0;=&#x000a0;intrinsic diffusivity; <italic>V</italic><sub>AD</sub>&#x000a0;=&#x000a0;extra-neurite transverse microscopic diffusivity; <italic>V</italic><sub>MD</sub>&#x000a0;=&#x000a0;extra-neurite microscopic mean diffusivity. **units mm<sup>2</sup>/s&#x000a0;&#x000d7;&#x000a0;10<sup>-3</sup></p></fn></table-wrap-foot></table-wrap><fig id="f0005"><label>Fig. 1</label><caption><p>Diffusion measurements that classified lesions in two types. Diffusion maps from the DTI (a, b) and MC-SMT models (c, d) can distinguish A and B types MS lesions: FA&#x000a0;=&#x000a0;fractional anisotropy; RD&#x000a0;=&#x000a0;radial diffusivity; &#x003bc;FA&#x000a0;=&#x000a0;microscopic fractional anisotropy; &#x00192;<sub>in</sub>&#x000a0;=&#x000a0;intra-neurite volume fraction.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0090">Compared to A-type lesions, B-type lesions had a lower FA, &#x003bc;FA and &#x00192;<sub>in</sub>, yet a higher RD, irrespective of the lesion location (P&#x000a0;&#x0003c;&#x000a0;0.001, <xref rid="t0015" ref-type="table">Table 3</xref> and <xref rid="s0105" ref-type="sec">Supplementary Table 1</xref>). Moreover, the lesion number of both types were similar at all the locations, except at the juxtacortical regions where the B-type lesions predominated (P&#x000a0;&#x0003c;&#x000a0;0.001). Most patients had both types of lesions, with between 40 and 70% of B-type lesions (<xref rid="s0105" ref-type="sec">Supplementary Fig. 1</xref>). Moreover, 27% of patients had 80% or more of one specific type of plaque, with a predominance of A-type lesions in 15% of the subjects, while 12% had mostly B-type lesions (see <xref rid="f0010" ref-type="fig">Fig. 2</xref>). However, there was no correlation between the overall number of A and B type lesions. By contrast, 64 and 63% of the lesion volume corresponded to B-type lesions in the whole brain and periventricular areas, respectively, suggesting that the plaques of this type were larger (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0105" ref-type="sec">Supplementary Fig. 2</xref>). The proportional volumes of B-type lesions but not their number was higher in the SPMS patients (mean percentage 90%) than in the RRMS patients (mean percentage 61%: 95% CI &#x02212;0.48 to &#x02212;0.10; P&#x000a0;&#x0003c;&#x000a0;0.01).<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Description of the B-type lesions compared to A-type lesions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Whole brain</th><th>Periventricular</th><th>Juxtacortical</th><th>Brainstem</th><th>Cerebellum</th><th>Deep WM</th></tr></thead><tbody><tr><td>Prediction strength of lesion classification</td><td>0.931</td><td>0.822</td><td>0.820</td><td>0.925</td><td>0.820</td><td>0.824</td></tr><tr><td>Percentage of B-type lesions</td><td>52%</td><td>54%</td><td>60% (P&#x000a0;&#x0003c;&#x000a0;0.001)</td><td>50%</td><td>53%</td><td>46%</td></tr><tr><td>Percentage of B-type lesions volume</td><td>64% (P&#x000a0;&#x0003c;&#x000a0;0.001)</td><td>63% (P&#x000a0;&#x0003c;&#x000a0;0.001)</td><td>50%</td><td>48%</td><td>50%</td><td>55%</td></tr><tr><td colspan="7">Differences between DTI-derived tensor metrics and microstructural diffusion properties comparing MS lesion types</td></tr><tr><td>&#x00394;FA</td><td>&#x02212;0.15</td><td>&#x02212;0.16</td><td>&#x02212;0.13</td><td>&#x02212;0.10</td><td>&#x02212;0.18</td><td>&#x02212;0.14</td></tr><tr><td>&#x00394;RD**</td><td>0.17</td><td>0.15</td><td>0.15</td><td>0.12</td><td>0.15</td><td>0.15</td></tr><tr><td>&#x00394;&#x003bc;FA</td><td>&#x02212;0.12</td><td>&#x02212;0.14</td><td>&#x02212;0.14</td><td>&#x02212;0.05</td><td>&#x02212;0.05</td><td>&#x02212;0.09</td></tr><tr><td>&#x00394;&#x00192;<sub>in</sub></td><td>&#x02212;0.20</td><td>&#x02212;0.16</td><td>&#x02212;0.14</td><td>&#x02212;0.27</td><td>&#x02212;0.22</td><td>&#x02212;0.19</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are given as the mean (standard deviation). All diffusion metrics showed significant differences (P&#x000a0;&#x0003c;&#x000a0;0.001) between A and B types lesions: FA&#x000a0;=&#x000a0;fractional anisotropy; RD&#x000a0;=&#x000a0;radial diffusivity; &#x003bc;FA&#x000a0;=&#x000a0;microscopic fractional anisotropy; &#x00192;<sub>in</sub>&#x000a0;=&#x000a0;intra-neurite volume fraction. &#x00394;&#x000a0;=&#x000a0;delta/difference. **units of mm<sup>2</sup>/s&#x000a0;&#x000d7;&#x000a0;10<sup>-3</sup>.</p></fn></table-wrap-foot></table-wrap><fig id="f0010"><label>Fig. 2</label><caption><p>Example of two patients that presented a predominant lesion type. Most lesions were classified as A-type (in green) in the patient in the left column, while the majority of lesions were B-type (in red) in the patient in the right column: FA&#x000a0;=&#x000a0;fractional anisotropy; RD&#x000a0;=&#x000a0;radial diffusivity; &#x003bc;FA&#x000a0;=&#x000a0;microscopic fractional anisotropy; &#x00192;<sub>in</sub>&#x000a0;=&#x000a0;intra-neurite volume fraction. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="s0065"><label>3.2</label><title>Association between MS lesion type and the clinical outcome</title><p id="p0095">At the patient-level, we detected several significant correlations between the overall number of B-type lesions and the clinical variables (P&#x000a0;&#x0003c;&#x000a0;0.05 controlling for the effect of age and gender: <xref rid="t0020" ref-type="table">Table 4</xref>). By contrast, we did not find any significant correlation between A-type lesions and the clinical data. Thus, a higher number of B-type lesions was associated with a higher MSSS, worse cerebellar function and worse cognition (Bonferroni-corrected P threshold&#x000a0;=&#x000a0;0.004). Juxtacortical and cerebellar lesions had the strongest correlation values. However, we failed to detect significant correlations with clinical data when the number of periventricular B-type lesions was considered.<table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Association between number of B-type lesions and the clinical variables, controlling for the effects of age and gender.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Global</th><th>Periventricular</th><th>Juxtacortical</th><th>Brainstem</th><th>Cerebellar</th><th>Deep WM</th></tr></thead><tbody><tr><td>MSSS</td><td>Positive (P&#x000a0;=&#x000a0;0.004)*</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.006)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.001)*</td><td>Positive (P&#x000a0;=&#x000a0;0.042)</td></tr><tr><td>EDSS</td><td>Positive (P&#x000a0;=&#x000a0;0.015)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.025)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.001)*</td><td>Positive (P&#x000a0;=&#x000a0;0.029)</td></tr><tr><td>Cerebellar functional system</td><td>Positive (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.001)*</td><td>n.s</td><td>Positive (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Positive (P&#x000a0;=&#x000a0;0.003)*</td></tr><tr><td>High-efficacy therapy</td><td>Positive (P&#x000a0;=&#x000a0;0.008)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.017)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.017)</td><td>Positive (P&#x000a0;=&#x000a0;0.016)</td></tr><tr><td colspan="7"><italic>Neuropsychological test battery</italic></td></tr><tr><td>Global cognitive score</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>n.s</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.001)*</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.002)*</td></tr><tr><td>zAttention</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>n.s</td><td>Negative (P&#x000a0;=&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.005)</td><td>Negative (P&#x000a0;=&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.002)*</td></tr><tr><td>zFluency</td><td>Negative (P&#x000a0;=&#x000a0;0.033)</td><td>n.s</td><td>n.s.</td><td>Negative (P&#x000a0;=&#x000a0;0.014)</td><td>Negative (P&#x000a0;=&#x000a0;0.007)</td><td>n.s</td></tr><tr><td>zVerbal memory</td><td>Negative (P&#x000a0;=&#x000a0;0.001)*</td><td>n.s</td><td>Negative (P&#x000a0;=&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.016)</td><td>Negative (P&#x000a0;=&#x000a0;0.004)</td><td>Negative (P&#x000a0;=&#x000a0;0.003)*</td></tr></tbody></table><table-wrap-foot><fn><p>MSSS&#x000a0;=&#x000a0;Multiple Sclerosis Severity Score; EDSS&#x000a0;=&#x000a0;Expanded Disability Status Scale; n.s.&#x000a0;=&#x000a0;not statistically significant; *, significant after a Bonferroni correction.</p></fn></table-wrap-foot></table-wrap></p><p id="p0100">In terms of lesion volume, the volume of B-type lesions was correlated with cerebellar function and cognitive disability. In particular, stronger correlations with clinical disability were found for periventricular lesions (<xref rid="t0025" ref-type="table">Table 5</xref>). However, there were no significant correlations with EDSS, brainstem and pyramidal functional systems, verbal fluency, visual memory deficits and the type of treatment after a Bonferroni correction.<table-wrap position="float" id="t0025"><label>Table 5</label><caption><p>Associations between the volume of B-type lesions and the clinical variables controlling for the effects of age and gender.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Whole brain</th><th>Periventricular</th><th>Juxtacortical</th><th>Brainstem</th><th>Cerebellar</th><th>Deep WM</th></tr></thead><tbody><tr><td>EDSS</td><td>Positive (P&#x000a0;=&#x000a0;0.021)</td><td>Positive (P&#x000a0;=&#x000a0;0.025)</td><td>n.s</td><td>n.s</td><td>n.s</td><td>n.s</td></tr><tr><td>Cerebellar functional system</td><td>Positive (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Positive (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Positive (P&#x000a0;=&#x000a0;0.014)</td><td>n.s</td><td>Positive (P&#x000a0;=&#x000a0;0.001)</td><td>n.s</td></tr><tr><td>Brainstem functional system</td><td>Positive (P&#x000a0;=&#x000a0;0.016)</td><td>Positive (P&#x000a0;=&#x000a0;0.014)</td><td>n.s.</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>Pyramidal functional system</td><td>Positive (P&#x000a0;=&#x000a0;0.010)</td><td>Positive (P&#x000a0;=&#x000a0;0.008)</td><td>n.s.</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>High-efficacy therapy</td><td>Positive (P&#x000a0;=&#x000a0;0.022)</td><td>Positive (P&#x000a0;=&#x000a0;0.022)</td><td>n.s</td><td>n.s</td><td>n.s</td><td>n.s</td></tr><tr><td colspan="7"><italic>Neuropsychological test battery</italic></td></tr><tr><td>Global cognitive score</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.029)</td><td>Negative (P&#x000a0;=&#x000a0;0.003)</td><td>n.s</td><td>n.s</td></tr><tr><td>zAttention</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;=&#x000a0;0.034)</td><td>Negative (P&#x000a0;=&#x000a0;0.037)</td><td>n.s.</td><td>n.s</td></tr><tr><td>zFluency</td><td>Negative (P&#x000a0;=&#x000a0;0.015)</td><td>Negative (P&#x000a0;=&#x000a0;0.019)</td><td>n.s</td><td>n.s</td><td>n.s</td><td>n.s</td></tr><tr><td>zVerbal memory</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>Negative (P&#x000a0;&#x0003c;&#x000a0;0.001)*</td><td>n.s</td><td>Negative (P&#x000a0;=&#x000a0;0.019)</td><td>n.s</td><td>Negative (P&#x000a0;=&#x000a0;0.016)</td></tr><tr><td>zVisual memory</td><td>Negative (P&#x000a0;=&#x000a0;0.012)</td><td>Negative (P&#x000a0;=&#x000a0;0.009)</td><td>n.s</td><td>n.s</td><td>n.s</td><td>n.s</td></tr></tbody></table><table-wrap-foot><fn><p>EDSS&#x000a0;=&#x000a0;Expanded Disability Status Scale; n.s.&#x000a0;=&#x000a0;not statistically significant; *, significant after a Bonferroni correction.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s0070"><label>4</label><title>Discussion</title><p id="p0105">In this study, we demonstrate that MS lesions can be classified into two types based on the severity of the changes in terms of macroscopic DTI parameters and microscopic diffusion properties. We found that most patients had both types of lesions, although in nearly a quarter of the cohort there was a clear predominance towards a given lesion type. B-type lesions are thought to present more severe tissue damage, and in terms of number and volume, the study demonstrates that their presence is related to a worse clinical evolution. Specifically, a larger number of B-type lesions in the juxtacortical, cerebellar and deep WM areas was more strongly associated with disability, as was a larger volume of these lesions in periventricular regions. All in all, the results support the usefulness of diffusion MRI to obtain information <italic>in vivo</italic> on the heterogeneity of the pathological changes in MS plaques.</p><p id="p0110">Our findings indicate that the combination of two diffusion-based models, DTI (FA and RD) and MC-SMT (&#x003bc;FA and &#x00192;<sub>in</sub>), which can capture how water moves in the tissue over distinct timescales, enables two distinct types of MS lesions to be classified with high predictive value. Lesions with larger modifications in diffusion imaging properties are crucial to characterize the two MS lesion types (A-type lesions show higher FA, &#x003bc;FA and &#x00192;<sub>in</sub>, and smaller RD values; while B-type lesions display lower FA, &#x003bc;FA and &#x00192;<sub>in</sub>, and higher RD values on <xref rid="s0105" ref-type="sec">Supplementary Fig. 3</xref>). B-type lesions are thought to be associated with more severe demyelination and axonal damage (<xref rid="b0210" ref-type="bibr">Yu et al., 2019</xref>). Therefore, the classification proposed would provide information regarding inflammatory destruction or the ability for neurorepair in a given patient, potentially representing a useful biomarker for phase II clinical trials.</p><p id="p0115">In previous studies, focal MS lesions display very heterogeneous DTI abnormalities, with a persistent decrease in FA values and an increase in the other diffusion coefficients compared to the NAWM (<xref rid="b0075" ref-type="bibr">Inglese and Bester, 2010</xref>). FA values preferentially reflect changes in axon density, whilst RD is a measure sensitive to myelin injury (<xref rid="b0025" ref-type="bibr">Beaulieu, 2002</xref>) . However, these diffusion features alone are not sufficiently specific to estimate the severity of damage. Moreover, their association with clinical disability is mild to moderate due to the large variability of DTI indices and the complex processes lesioned tissues undergo (<xref rid="b0040" ref-type="bibr">Filippi et al., 2001</xref>). Conversely, &#x003bc;FA and &#x00192;<sub>in</sub> provide information regarding more specific features at the microstructural level, depicting restricted anisotropic diffusion into the intracellular water domain (<xref rid="b0090" ref-type="bibr">Kaden et al., 2008</xref>). Accordingly, despite the MC-SMT model does not allow the quantification of non-monoexponential behavior to describe the deviation of diffusion displacement from the Gaussian profile specifically (<xref rid="b0080" ref-type="bibr">Jensen et al., 2005</xref>), a significant decrease of &#x003bc;FA and &#x00192;<sub>in</sub> have been demonstrated for different degrees of brain and SC tissue damage in MS compared with normal WM tissue (<xref rid="b0035" ref-type="bibr">By et al., 2018</xref>, <xref rid="b0110" ref-type="bibr">Lakhani et al., 2020</xref>). Furthermore, such microscopic features seem to be able to distinguish MS lesions with more axonal damage from the lesions that are hyperintense in T2-weighted sequences (<xref rid="b0010" ref-type="bibr">Bagnato et al., 2019</xref>, <xref rid="b0030" ref-type="bibr">Bonet-Carne et al., 2019</xref>), identified as black-holes in T1-spin echo sequences (<xref rid="b0200" ref-type="bibr">van Walderveen et al., 1998</xref>). When compared with the observation of black holes, the use of quantitative diffusion metrics increases the accuracy and reproducibility of the results. Thus, our findings highlight the complementarity of DTI and SC-SMT metrics to define the characteristics of MS lesions.</p><p id="p0120">The proportion of A and B type lesions was similar across the brain, except in juxtacortical areas where B-type lesions predominate. In periventricular regions, most of the lesion volume corresponds to B-type lesions, and such regional differences could reflect the nature of MS lesions in terms of their formation and evolution. This hypothesis is supported by the predominance of B-type lesions in SPMS patients (mean&#x000a0;=&#x000a0;90%). Nevertheless, further longitudinal studies will be required to decipher the chronicity of those lesions and to assess whether they are related to slowly expanding plaques.</p><p id="p0125">Previous studies showed that focal MS lesions, a hallmark of the disease, are weakly correlated with clinical disability (<xref rid="b0015" ref-type="bibr">Barkhof, 2002</xref>) and disease severity (<xref rid="b0135" ref-type="bibr">Mostert et al., 2010</xref>). However, our findings demonstrate that the number and volume of specific B-type lesions were strongly associated with a more severe disease evolution (correlation coefficients between 0.4 and 0.67), with a worse physical (mainly related to cerebellar functions) and cognitive disability. The lack of correlation with the EDSS after correcting for multiple comparisons could be influenced by the strong influence of SC integrity on the EDSS (<xref rid="b0160" ref-type="bibr">Rocca et al., 2017</xref>), a fact that was not assessed here. Specifically, the number and volume of B-type lesions in juxtacortical and cerebellar areas, and their volume in periventricular regions, were the features that were most strongly correlated with disease evolution and disability. Indeed, periventricular damage may affect large white matter tracts, such as the cingulum and frontoparietal connections, potentially contributing to the cognitive deficits in patients with MS (<xref rid="b0190" ref-type="bibr">Tiemann et al., 2009</xref>, <xref rid="b0180" ref-type="bibr">Solana et al., 2018</xref>). Previous studies reported results consistent with the present findings, correlating brain lesion with a worsening in clinical disability, particularly for T1 hypointense lesions (<xref rid="b0060" ref-type="bibr">Giorgio et al., 2014</xref>). Together, the presence of lesions with larger diffusion changes could reflect a destructive pattern of chronically demyelinated axons and more neuroaxonal damage, which is related to more severe disease evolution.</p><p id="p0130">This study has several limitations that should be considered for future research. First, our findings should be validated through histological studies to characterize the underlying tissue changes in the A and B type lesions, and their correspondence with active, chronic or chronic active lesions. Second, diffusion metrics are highly dependent on acquisition and scanner parameters, although they are very reproducible in scan-rescan experiments (<xref rid="b0035" ref-type="bibr">By et al., 2018</xref>). Consequently, it is important to harmonize the techniques for clinical trials that focus on different sites and protocols (<xref rid="b0055" ref-type="bibr">Fortin et al., 2017</xref>). Finally, we did not evaluate the specific microscopic and macroscopic changes in new T1-enhancing lesions, in black holes or over time, and thus, longitudinal studies would be useful to understand the MS temporal evolution and their predictive value in a prospective manner.</p></sec><sec id="s0075"><label>5</label><title>Conclusions</title><p id="p0135">Microscopic features of the intracellular water domain (&#x003bc;FA and &#x00192;<sub>in</sub>) and macroscopic DTI-derived metrics (FA, RD) together contribute to define the amount of damage within MS lesions. In turn, these features provide a specific pattern of lesion severity that helps understand the mechanisms underlying clinical disability and cognitive impairment in MS patients. Accordingly, the classification of lesion types has the potential to ensure MS patients receive more specific and better-targeted therapies.</p></sec><sec id="s0080"><title>CRediT authorship contribution statement</title><p id="p0140"><bold>Eloy Mart&#x000ed;nez-Heras:</bold> Conceptualization, Methodology, Software, Validation, Investigation, Writing - original draft, Visualization, Supervision. <bold>Elisabeth Solana:</bold> Conceptualization, Methodology, Software, Validation, Investigation, Writing - original draft, Visualization, Supervision. <bold>Ferran Prados:</bold> Formal analysis, Software, Supervision. <bold>Mag&#x000ed; Andorr&#x000e0;:</bold> . <bold>Aleix Solanes:</bold> Formal analysis, Software, Supervision. <bold>Elisabet L&#x000f3;pez-Soley:</bold> Writing - review &#x00026; editing. <bold>Carmen Montejo:</bold> Writing - review &#x00026; editing. <bold>Irene Pulido-Valdeolivas:</bold> Writing - review &#x00026; editing. <bold>Salut Alba-Arbalat:</bold> Writing - review &#x00026; editing. <bold>Nuria Sola-Valls:</bold> Writing - review &#x00026; editing. <bold>Maria Sep&#x000fa;lveda:</bold> Writing - review &#x00026; editing. <bold>Yolanda Blanco:</bold> Writing - review &#x00026; editing. <bold>Albert Saiz:</bold> Resources, Supervision, Writing - review &#x00026; editing, Funding acquisition. <bold>Joaquim Radua:</bold> Formal analysis, Software, Supervision, Writing - review &#x00026; editing. <bold>Sara Llufriu:</bold> Conceptualization, Investigation, Resources, Writing - review &#x00026; editing, Supervision, Funding acquisition.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0145">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Absinta</surname><given-names>M.</given-names></name><name><surname>Sati</surname><given-names>P.</given-names></name><name><surname>Masuzzo</surname><given-names>F.</given-names></name><name><surname>Nair</surname><given-names>G.</given-names></name><name><surname>Sethi</surname><given-names>V.</given-names></name><name><surname>Kolb</surname><given-names>H.</given-names></name><name><surname>Ohayon</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Cortese</surname><given-names>I.C.M.</given-names></name><name><surname>Reich</surname><given-names>D.S.</given-names></name></person-group><article-title>Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo</article-title><source>JAMA Neurol</source><year>2019</year><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.2399</pub-id></element-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Bagnato</surname><given-names>F.</given-names></name><name><surname>Franco</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Kaden</surname><given-names>E.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Alexander</surname><given-names>D.C.</given-names></name><name><surname>Smith</surname><given-names>S.A.</given-names></name><name><surname>Dortch</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Probing axons using multi-compartmental diffusion in multiple sclerosis</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2019</year><pub-id pub-id-type="doi">10.1002/acn3.50836</pub-id></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Barkhof</surname><given-names>F.</given-names></name></person-group><article-title>The clinico-radiological paradox in multiple sclerosis revisited</article-title><source>Curr. Opin. Neurol.</source><volume>15</volume><year>2002</year><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">12045719</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Basser</surname><given-names>P.J.</given-names></name><name><surname>Mattiello</surname><given-names>J.</given-names></name><name><surname>LeBihan</surname><given-names>D.</given-names></name></person-group><article-title>Estimation of the effective self-diffusion tensor from the NMR spin echo</article-title><source>J. Magn. Reson. B</source><volume>103</volume><year>1994</year><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">8019776</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Beaulieu</surname><given-names>C.</given-names></name></person-group><article-title>The basis of anisotropic water diffusion in the nervous system - a technical review</article-title><source>NMR Biomed.</source><volume>15</volume><year>2002</year><fpage>435</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">12489094</pub-id></element-citation></ref><ref id="b0030"><element-citation publication-type="book" id="h0030"><person-group person-group-type="author"><name><surname>Bonet-Carne</surname><given-names>E.</given-names></name><name><surname>Grussu</surname><given-names>F.</given-names></name><name><surname>Ning</surname><given-names>L.</given-names></name><name><surname>Sepehrband</surname><given-names>F.</given-names></name><name><surname>Tax</surname><given-names>C.M.W.</given-names></name></person-group><chapter-title>Computational Diffusion MRI: International MICCAI Workshop, Granada, Spain, September 2018</chapter-title><year>2019</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>By</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Box</surname><given-names>B.A.</given-names></name><name><surname>Bagnato</surname><given-names>F.R.</given-names></name><name><surname>Smith</surname><given-names>S.A.</given-names></name></person-group><article-title>Multi-compartmental diffusion characterization of the human cervical spinal cord in vivo using the spherical mean technique</article-title><source>NMR Biomed.</source><volume>31</volume><year>2018</year><object-id pub-id-type="publisher-id">e3894</object-id></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M.</given-names></name><name><surname>Cercignani</surname><given-names>M.</given-names></name><name><surname>Inglese</surname><given-names>M.</given-names></name><name><surname>Horsfield</surname><given-names>M.A.</given-names></name><name><surname>Comi</surname><given-names>G.</given-names></name></person-group><article-title>Diffusion tensor magnetic resonance imaging in multiple sclerosis</article-title><source>Neurology</source><year>2001</year><pub-id pub-id-type="doi">10.1212/wnl.56.3.304</pub-id></element-citation></ref><ref id="b0045"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M.</given-names></name><name><surname>Preziosa</surname><given-names>P.</given-names></name><name><surname>Banwell</surname><given-names>B.L.</given-names></name><name><surname>Barkhof</surname><given-names>F.</given-names></name><name><surname>Ciccarelli</surname><given-names>O.</given-names></name><name><surname>De Stefano</surname><given-names>N.</given-names></name><name><surname>Geurts</surname><given-names>J.J.G.</given-names></name><name><surname>Paul</surname><given-names>F.</given-names></name><name><surname>Reich</surname><given-names>D.S.</given-names></name><name><surname>Toosy</surname><given-names>A.T.</given-names></name><name><surname>Traboulsee</surname><given-names>A.</given-names></name><name><surname>Wattjes</surname><given-names>M.P.</given-names></name><name><surname>Yousry</surname><given-names>T.A.</given-names></name><name><surname>Gass</surname><given-names>A.</given-names></name><name><surname>Lubetzki</surname><given-names>C.</given-names></name><name><surname>Weinshenker</surname><given-names>B.G.</given-names></name><name><surname>Rocca</surname><given-names>M.A.</given-names></name></person-group><article-title>Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines</article-title><source>Brain</source><volume>142</volume><year>2019</year><fpage>1858</fpage><lpage>1875</lpage><pub-id pub-id-type="pmid">31209474</pub-id></element-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M.</given-names></name><name><surname>Rocca</surname><given-names>M.A.</given-names></name></person-group><article-title>MR Imaging of Multiple Sclerosis</article-title><source>Radiology</source><year>2011</year><pub-id pub-id-type="doi">10.1148/radiol.11101362</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Fortin</surname><given-names>J.-P.</given-names></name><name><surname>Parker</surname><given-names>D.</given-names></name><name><surname>Tun&#x000e7;</surname><given-names>B.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Elliott</surname><given-names>M.A.</given-names></name><name><surname>Ruparel</surname><given-names>K.</given-names></name><name><surname>Roalf</surname><given-names>D.R.</given-names></name><name><surname>Satterthwaite</surname><given-names>T.D.</given-names></name><name><surname>Gur</surname><given-names>R.C.</given-names></name><name><surname>Gur</surname><given-names>R.E.</given-names></name><name><surname>Schultz</surname><given-names>R.T.</given-names></name><name><surname>Verma</surname><given-names>R.</given-names></name><name><surname>Shinohara</surname><given-names>R.T.</given-names></name></person-group><article-title>Harmonization of multi-site diffusion tensor imaging data</article-title><source>Neuroimage</source><volume>161</volume><year>2017</year><fpage>149</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">28826946</pub-id></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>A.</given-names></name><name><surname>Stromillo</surname><given-names>M.L.</given-names></name><name><surname>Bartolozzi</surname><given-names>M.L.</given-names></name><name><surname>Rossi</surname><given-names>F.</given-names></name><name><surname>Battaglini</surname><given-names>M.</given-names></name><name><surname>De Leucio</surname><given-names>A.</given-names></name><name><surname>Guidi</surname><given-names>L.</given-names></name><name><surname>Maritato</surname><given-names>P.</given-names></name><name><surname>Portaccio</surname><given-names>E.</given-names></name><name><surname>Sormani</surname><given-names>M.P.</given-names></name><name><surname>Amato</surname><given-names>M.P.</given-names></name><name><surname>De Stefano</surname><given-names>N.</given-names></name></person-group><article-title>Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis</article-title><source>Mult. Scler.</source><volume>20</volume><year>2014</year><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">23877971</pub-id></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Greve</surname><given-names>D.N.</given-names></name><name><surname>Fischl</surname><given-names>B.</given-names></name></person-group><article-title>Accurate and robust brain image alignment using boundary-based registration</article-title><source>NeuroImage</source><year>2009</year><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.06.060</pub-id></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Griffanti</surname><given-names>L.</given-names></name><name><surname>Jenkinson</surname><given-names>M.</given-names></name><name><surname>Suri</surname><given-names>S.</given-names></name><name><surname>Zsoldos</surname><given-names>E.</given-names></name><name><surname>Mahmood</surname><given-names>A.</given-names></name><name><surname>Filippini</surname><given-names>N.</given-names></name><name><surname>Sexton</surname><given-names>C.E.</given-names></name><name><surname>Topiwala</surname><given-names>A.</given-names></name><name><surname>Allan</surname><given-names>C.</given-names></name><name><surname>Kivim&#x000e4;ki</surname><given-names>M.</given-names></name><name><surname>Singh-Manoux</surname><given-names>A.</given-names></name><name><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name><surname>Mackay</surname><given-names>C.E.</given-names></name><name><surname>Zamboni</surname><given-names>G.</given-names></name></person-group><article-title>Classification and characterization of periventricular and deep white matter hyperintensities on MRI: A study in older adults</article-title><source>Neuroimage</source><volume>170</volume><year>2018</year><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">28315460</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Inglese</surname><given-names>M.</given-names></name><name><surname>Bester</surname><given-names>M.</given-names></name></person-group><article-title>Diffusion imaging in multiple sclerosis: research and clinical implications</article-title><source>NMR Biomed.</source><volume>23</volume><year>2010</year><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">20882528</pub-id></element-citation></ref><ref id="b0080"><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>J.H.</given-names></name><name><surname>Helpern</surname><given-names>J.A.</given-names></name><name><surname>Ramani</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Kaczynski</surname><given-names>K.</given-names></name></person-group><article-title>Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging</article-title><source>Magn. Reson. Med.</source><volume>53</volume><year>2005</year><fpage>1432</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">15906300</pub-id></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D.K.</given-names></name><name><surname>Alexander</surname><given-names>D.C.</given-names></name><name><surname>Bowtell</surname><given-names>R.</given-names></name><name><surname>Cercignani</surname><given-names>M.</given-names></name><name><surname>Dell&#x02019;Acqua</surname><given-names>F.</given-names></name><name><surname>McHugh</surname><given-names>D.J.</given-names></name><name><surname>Miller</surname><given-names>K.L.</given-names></name><name><surname>Palombo</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>G.J.M.</given-names></name><name><surname>Rudrapatna</surname><given-names>U.S.</given-names></name><name><surname>Tax</surname><given-names>C.M.W.</given-names></name></person-group><article-title>Microstructural imaging of the human brain with a &#x0201c;super-scanner&#x0201d;: 10 key advantages of ultra-strong gradients for diffusion MRI</article-title><source>NeuroImage</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.05.047</pub-id></element-citation></ref><ref id="b0090"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Kaden</surname><given-names>E.</given-names></name><name><surname>Anwander</surname><given-names>A.</given-names></name><name><surname>Kn&#x000f6;sche</surname><given-names>T.R.</given-names></name></person-group><article-title>Variational inference of the fiber orientation density using diffusion MR imaging</article-title><source>Neuroimage</source><volume>42</volume><year>2008</year><fpage>1366</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">18603006</pub-id></element-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Kaden</surname><given-names>E.</given-names></name><name><surname>Kruggel</surname><given-names>F.</given-names></name><name><surname>Alexander</surname><given-names>D.C.</given-names></name></person-group><article-title>Quantitative mapping of the per-axon diffusion coefficients in brain white matter</article-title><source>Magn. Reson. Med.</source><volume>75</volume><year>2016</year><fpage>1752</fpage><lpage>1763</lpage><pub-id pub-id-type="pmid">25974332</pub-id></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>C.D.</given-names></name><name><surname>Ackerman</surname><given-names>J.J.H.</given-names></name><name><surname>Yablonskiy</surname><given-names>D.A.</given-names></name></person-group><article-title>On the nature of the NAA diffusion attenuated MR signal in the central nervous system</article-title><source>Magn. Reson. Med.</source><volume>52</volume><year>2004</year><fpage>1052</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">15508157</pub-id></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>J.F.</given-names></name></person-group><article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title><source>Neurology</source><volume>33</volume><year>1983</year><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">6685237</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Lakhani</surname><given-names>D.A.</given-names></name><name><surname>Schilling</surname><given-names>K.G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Bagnato</surname><given-names>F.</given-names></name></person-group><article-title>Advanced Multicompartment Diffusion MRI Models and Their Application in Multiple Sclerosis</article-title><source>AJNR Am. J. Neuroradiol.</source><volume>41</volume><year>2020</year><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">32354707</pub-id></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Lassmann</surname><given-names>H.</given-names></name><name><surname>Br&#x000fc;ck</surname><given-names>W.</given-names></name><name><surname>Lucchinetti</surname><given-names>C.F.</given-names></name></person-group><article-title>The immunopathology of multiple sclerosis: an overview</article-title><source>Brain Pathol.</source><volume>17</volume><year>2007</year><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">17388952</pub-id></element-citation></ref><ref id="b0120"><mixed-citation publication-type="other" id="h0120">Lucchinetti, C., Br&#x000fc;ck, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H., 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology.</mixed-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Ludwin</surname><given-names>S.K.</given-names></name></person-group><article-title>The pathogenesis of multiple sclerosis: relating human pathology to experimental studies</article-title><source>J. Neuropathol. Exp. Neurol.</source><volume>65</volume><year>2006</year><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">16691112</pub-id></element-citation></ref><ref id="b0130"><mixed-citation publication-type="other" id="h0130">Mollink, J., Kleinnijenhuis, M., van Cappellen van Walsum, A.-M., Sotiropoulos, S.N., Cottaar, M., Mirfin, C., Heinrich, M.P., Jenkinson, M., Pallebage-Gamarallage, M., Ansorge, O., Jbabdi, S., Miller, K.L., 2017. Evaluating fibre orientation dispersion in white matter: Comparison of diffusion MRI, histology and polarized light imaging. Neuroimage 157, 561&#x02013;574.</mixed-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Mostert</surname><given-names>J.P.</given-names></name><name><surname>Koch</surname><given-names>M.W.</given-names></name><name><surname>Steen</surname><given-names>C.</given-names></name><name><surname>Heersema</surname><given-names>D.J.</given-names></name><name><surname>De Groot</surname><given-names>J.C.</given-names></name><name><surname>De Keyser</surname><given-names>J.</given-names></name></person-group><article-title>T2 lesions and rate of progression of disability in multiple sclerosis</article-title><source>Eur. J. Neurol.</source><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03093.x</pub-id></element-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Novikov</surname><given-names>D.S.</given-names></name><name><surname>Fieremans</surname><given-names>E.</given-names></name><name><surname>Jespersen</surname><given-names>S.N.</given-names></name><name><surname>Kiselev</surname><given-names>V.G.</given-names></name></person-group><article-title>Quantifying brain microstructure with diffusion MRI: Theory and parameter estimation</article-title><source>NMR Biomed.</source><volume>32</volume><year>2019</year><object-id pub-id-type="publisher-id">e3998</object-id></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Polman</surname><given-names>C.H.</given-names></name><name><surname>Reingold</surname><given-names>S.C.</given-names></name><name><surname>Banwell</surname><given-names>B.</given-names></name><name><surname>Clanet</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>J.A.</given-names></name><name><surname>Filippi</surname><given-names>M.</given-names></name><name><surname>Fujihara</surname><given-names>K.</given-names></name><name><surname>Havrdova</surname><given-names>E.</given-names></name><name><surname>Hutchinson</surname><given-names>M.</given-names></name><name><surname>Kappos</surname><given-names>L.</given-names></name><name><surname>Lublin</surname><given-names>F.D.</given-names></name><name><surname>Montalban</surname><given-names>X.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>P.</given-names></name><name><surname>Sandberg-Wollheim</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>A.J.</given-names></name><name><surname>Waubant</surname><given-names>E.</given-names></name><name><surname>Weinshenker</surname><given-names>B.</given-names></name><name><surname>Wolinsky</surname><given-names>J.S.</given-names></name></person-group><article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title><source>Ann. Neurol.</source><volume>69</volume><year>2011</year><fpage>292</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">21387374</pub-id></element-citation></ref><ref id="b0150"><mixed-citation publication-type="other" id="h0150">Rao, S.M., Leo, G.J., Bernardin, L., Unverzagt, F., 1991. Cognitive dysfunction in multiple sclerosis.: I. Frequency, patterns, and prediction. Neurology. https://doi.org/10.1212/wnl.41.5.685.</mixed-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Rocca</surname><given-names>M.A.</given-names></name><name><surname>Amato</surname><given-names>M.P.</given-names></name><name><surname>De Stefano</surname><given-names>N.</given-names></name><name><surname>Enzinger</surname><given-names>C.</given-names></name><name><surname>Geurts</surname><given-names>J.J.</given-names></name><name><surname>Penner</surname><given-names>I.-K.</given-names></name><name><surname>Rovira</surname><given-names>A.</given-names></name><name><surname>Sumowski</surname><given-names>J.F.</given-names></name><name><surname>Valsasina</surname><given-names>P.</given-names></name><name><surname>Filippi</surname><given-names>M.</given-names></name></person-group><article-title>Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis</article-title><source>The Lancet Neurology</source><year>2015</year><pub-id pub-id-type="doi">10.1016/s1474-4422(14)70250-9</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Rocca</surname><given-names>M.A.</given-names></name><name><surname>Comi</surname><given-names>G.</given-names></name><name><surname>Filippi</surname><given-names>M.</given-names></name></person-group><article-title>The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis</article-title><source>Front. Neurol.</source><volume>8</volume><year>2017</year><fpage>433</fpage><pub-id pub-id-type="pmid">28928705</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Rovaris</surname><given-names>M.</given-names></name><name><surname>Gallo</surname><given-names>A.</given-names></name><name><surname>Valsasina</surname><given-names>P.</given-names></name><name><surname>Benedetti</surname><given-names>B.</given-names></name><name><surname>Caputo</surname><given-names>D.</given-names></name><name><surname>Ghezzi</surname><given-names>A.</given-names></name><name><surname>Montanari</surname><given-names>E.</given-names></name><name><surname>Sormani</surname><given-names>M.P.</given-names></name><name><surname>Bertolotto</surname><given-names>A.</given-names></name><name><surname>Mancardi</surname><given-names>G.</given-names></name><name><surname>Bergamaschi</surname><given-names>R.</given-names></name><name><surname>Martinelli</surname><given-names>V.</given-names></name><name><surname>Comi</surname><given-names>G.</given-names></name><name><surname>Filippi</surname><given-names>M.</given-names></name></person-group><article-title>Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI</article-title><source>Neuroimage</source><volume>24</volume><year>2005</year><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">15670691</pub-id></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Roxburgh</surname><given-names>R.H.S.R.</given-names></name><name><surname>Seaman</surname><given-names>S.R.</given-names></name><name><surname>Masterman</surname><given-names>T.</given-names></name><name><surname>Hensiek</surname><given-names>A.E.</given-names></name><name><surname>Sawcer</surname><given-names>S.J.</given-names></name><name><surname>Vukusic</surname><given-names>S.</given-names></name><name><surname>Achiti</surname><given-names>I.</given-names></name><name><surname>Confavreux</surname><given-names>C.</given-names></name><name><surname>Coustans</surname><given-names>M.</given-names></name><name><surname>le Page</surname><given-names>E.</given-names></name><name><surname>Edan</surname><given-names>G.</given-names></name><name><surname>McDonnell</surname><given-names>G.V.</given-names></name><name><surname>Hawkins</surname><given-names>S.</given-names></name><name><surname>Trojano</surname><given-names>M.</given-names></name><name><surname>Liguori</surname><given-names>M.</given-names></name><name><surname>Cocco</surname><given-names>E.</given-names></name><name><surname>Marrosu</surname><given-names>M.G.</given-names></name><name><surname>Tesser</surname><given-names>F.</given-names></name><name><surname>Leone</surname><given-names>M.A.</given-names></name><name><surname>Weber</surname><given-names>A.</given-names></name><name><surname>Zipp</surname><given-names>F.</given-names></name><name><surname>Miterski</surname><given-names>B.</given-names></name><name><surname>Epplen</surname><given-names>J.T.</given-names></name><name><surname>Oturai</surname><given-names>A.</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>P.S.</given-names></name><name><surname>Celius</surname><given-names>E.G.</given-names></name><name><surname>Lara</surname><given-names>N.T.</given-names></name><name><surname>Montalban</surname><given-names>X.</given-names></name><name><surname>Villoslada</surname><given-names>P.</given-names></name><name><surname>Silva</surname><given-names>A.M.</given-names></name><name><surname>Marta</surname><given-names>M.</given-names></name><name><surname>Leite</surname><given-names>I.</given-names></name><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Rubio</surname><given-names>J.</given-names></name><name><surname>Butzkueven</surname><given-names>H.</given-names></name><name><surname>Kilpatrick</surname><given-names>T.</given-names></name><name><surname>Mycko</surname><given-names>M.P.</given-names></name><name><surname>Selmaj</surname><given-names>K.W.</given-names></name><name><surname>Rio</surname><given-names>M.E.</given-names></name><name><surname>S&#x000e1;</surname><given-names>M.</given-names></name><name><surname>Salemi</surname><given-names>G.</given-names></name><name><surname>Savettieri</surname><given-names>G.</given-names></name><name><surname>Hillert</surname><given-names>J.</given-names></name><name><surname>Compston</surname><given-names>D.A.S.</given-names></name></person-group><article-title>Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity</article-title><source>Neurology</source><volume>64</volume><year>2005</year><fpage>1144</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">15824338</pub-id></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Sepulcre</surname><given-names>J.</given-names></name><name><surname>Vanotti</surname><given-names>S.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>R.</given-names></name><name><surname>Sandoval</surname><given-names>G.</given-names></name><name><surname>C&#x000e1;ceres</surname><given-names>F.</given-names></name><name><surname>Garcea</surname><given-names>O.</given-names></name><name><surname>Villoslada</surname><given-names>P.</given-names></name></person-group><article-title>Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test</article-title><source>Mult. Scler.</source><volume>12</volume><year>2006</year><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">16629422</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Solana</surname><given-names>E.</given-names></name><name><surname>Martinez-Heras</surname><given-names>E.</given-names></name><name><surname>Martinez-Lapiscina</surname><given-names>E.H.</given-names></name><name><surname>Sepulveda</surname><given-names>M.</given-names></name><name><surname>Sola-Valls</surname><given-names>N.</given-names></name><name><surname>Bargall&#x000f3;</surname><given-names>N.</given-names></name><name><surname>Berenguer</surname><given-names>J.</given-names></name><name><surname>Blanco</surname><given-names>Y.</given-names></name><name><surname>Andorra</surname><given-names>M.</given-names></name><name><surname>Pulido-Valdeolivas</surname><given-names>I.</given-names></name><name><surname>Zubizarreta</surname><given-names>I.</given-names></name><name><surname>Saiz</surname><given-names>A.</given-names></name><name><surname>Llufriu</surname><given-names>S.</given-names></name></person-group><article-title>Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis</article-title><source>Neuroimage Clin</source><volume>20</volume><year>2018</year><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">30094165</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R.</given-names></name><name><surname>Walther</surname><given-names>G.</given-names></name></person-group><article-title>Cluster Validation by Prediction Strength</article-title><source>Journal of Computational and Graphical Statistics</source><year>2005</year><pub-id pub-id-type="doi">10.1198/106186005x59243</pub-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Tiemann</surname><given-names>L.</given-names></name><name><surname>Penner</surname><given-names>I.K.</given-names></name><name><surname>Haupts</surname><given-names>M.</given-names></name><name><surname>Schlegel</surname><given-names>U.</given-names></name><name><surname>Calabrese</surname><given-names>P.</given-names></name></person-group><article-title>Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns</article-title><source>Mult. Scler.</source><volume>15</volume><year>2009</year><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">19667010</pub-id></element-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Tournier</surname><given-names>J.-D.</given-names></name><name><surname>Smith</surname><given-names>R.</given-names></name><name><surname>Raffelt</surname><given-names>D.</given-names></name><name><surname>Tabbara</surname><given-names>R.</given-names></name><name><surname>Dhollander</surname><given-names>T.</given-names></name><name><surname>Pietsch</surname><given-names>M.</given-names></name><name><surname>Christiaens</surname><given-names>D.</given-names></name><name><surname>Jeurissen</surname><given-names>B.</given-names></name><name><surname>Yeh</surname><given-names>C.-H.</given-names></name><name><surname>Connelly</surname><given-names>A.</given-names></name></person-group><article-title>MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation</article-title><source>Neuroimage</source><volume>202</volume><year>2019</year><object-id pub-id-type="publisher-id">116137</object-id></element-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>van Walderveen</surname><given-names>M.A.</given-names></name><name><surname>Kamphorst</surname><given-names>W.</given-names></name><name><surname>Scheltens</surname><given-names>P.</given-names></name><name><surname>van Waesberghe</surname><given-names>J.H.</given-names></name><name><surname>Ravid</surname><given-names>R.</given-names></name><name><surname>Valk</surname><given-names>J.</given-names></name><name><surname>Polman</surname><given-names>C.H.</given-names></name><name><surname>Barkhof</surname><given-names>F.</given-names></name></person-group><article-title>Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis</article-title><source>Neurology</source><volume>50</volume><year>1998</year><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">9595975</pub-id></element-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>A.M.</given-names></name><name><surname>Ridgway</surname><given-names>G.R.</given-names></name><name><surname>Webster</surname><given-names>M.A.</given-names></name><name><surname>Smith</surname><given-names>S.M.</given-names></name><name><surname>Nichols</surname><given-names>T.E.</given-names></name></person-group><article-title>Permutation inference for the general linear model</article-title><source>Neuroimage</source><volume>92</volume><year>2014</year><fpage>381</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">24530839</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>Q.</given-names></name><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Ngamsombat</surname><given-names>C.</given-names></name><name><surname>Machado</surname><given-names>N.</given-names></name><name><surname>Bireley</surname><given-names>J.D.</given-names></name><name><surname>Russo</surname><given-names>A.W.</given-names></name><name><surname>Nummenmaa</surname><given-names>A.</given-names></name><name><surname>Witzel</surname><given-names>T.</given-names></name><name><surname>Wald</surname><given-names>L.L.</given-names></name><name><surname>Klawiter</surname><given-names>E.C.</given-names></name><name><surname>Huang</surname><given-names>S.Y.</given-names></name></person-group><article-title>Imaging G-Ratio in Multiple Sclerosis Using High-Gradient Diffusion MRI and Macromolecular Tissue Volume</article-title><source>Am. J. Neuroradiol.</source><year>2019</year><pub-id pub-id-type="doi">10.3174/ajnr.a6283</pub-id></element-citation></ref></ref-list><sec id="s0105" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0170">The following are the Supplementary data to this article:<fig id="f0015" position="anchor"><label>Supplementary figure 1</label><graphic xlink:href="fx1"/></fig></p><p id="p0175"><fig id="f0020" position="anchor"><label>Supplementary figure 2</label><graphic xlink:href="fx2"/></fig></p><p id="p0180"><fig id="f0025" position="anchor"><label>Supplementary figure 3</label><graphic xlink:href="fx3"/></fig></p><p id="p0185"><supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p></sec><ack id="ak005"><sec id="s0085"><title>Acknowledgements</title><p id="p0150">The authors are grateful to Dr N&#x000fa;ria Bargall&#x000f3;, Cesar Garrido and the IDIBAPS Magnetic resonance imaging facility, and to the Fundaci&#x000f3; Cellex, for their support during the realization of the study. This work was carried out in the Esther Koplowitz building at IDIBAPS (Barcelona), part of the CERCA Programme/Generalitat de Catalunya.</p></sec><sec id="s0090"><title>Funding Statement</title><p id="p0155">The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article. This work was funded by: Proyectos de Investigaci&#x000f3;n en Salud (FIS 2015. PI15/00587, SL, AS; FIS 2018 PI18/01030, SL, AS), integrated into the Plan Estatal de Investigaci&#x000f3;n Cient&#x000ed;fica y T&#x000e9;cnica de Innovaci&#x000f3;n I&#x000a0;+&#x000a0;D&#x000a0;+&#x000a0;I, and co-funded by the <funding-source id="gp025"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos</institution></institution-wrap></funding-source> III-Subdirecci&#x000f3;n General de Evaluaci&#x000f3;n and the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100008530</institution-id><institution>Fondo Europeo de Desarrollo Regional</institution></institution-wrap></funding-source> (FEDER, &#x0201c;Otra manera de hacer Europa&#x0201d;); the <funding-source id="gp010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100007747</institution-id><institution>Red Espa&#x000f1;ola de Esclerosis M&#x000fa;ltiple</institution></institution-wrap></funding-source> (REEM: RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02); Ayuda <funding-source id="gp040"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source> de Investigaci&#x000f3;n 2017; the Premi Fundaci&#x000f3; Societat Catalana de Neurologia 2017; TEVA SLU; and the Fundaci&#x000f3; Cellex. EL-S holds a predoctorate grant from the <funding-source id="gp035"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100005774</institution-id><institution>University of Barcelona</institution></institution-wrap></funding-source> (APIF). AP-U is supported by the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1) and the Fundaci&#x000f3;n Alfonso Martin Escudero. This work was supported by Miguel Servet Research Contract (CPII19/00009) to J.R. and Research Project PI19/00394 from the Plan Nacional de I&#x000a0;+&#x000a0;D&#x000a0;+&#x000a0;i 2013&#x02013;2016, the <funding-source id="gp020"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos</institution></institution-wrap></funding-source> III-Subdirecci&#x000f3;n General de Evaluaci&#x000f3;n y Fomento de la Investigaci&#x000f3;n and the <funding-source id="gp015"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100008530</institution-id><institution>European Regional Development Fund</institution></institution-wrap></funding-source> (FEDER, &#x02018;Investing in your future&#x02019;). The funding bodies had no role in the design and performance of the study; the collection, management, analysis and interpretation of the data; the preparation, revision or approval of the manuscript; and the decision to submit the manuscript for publication.</p></sec><sec id="s0095"><title>Declaration of Competing Interest</title><p id="p0160">The author(s) declare the following potential conflicts of interest with respect to the research, authorship and/or the publication of this article: EM-H, AS, ES and JR have no conflict of interests to declare. MA holds equities in Bionure and Goodgut; EL-S received funding from the University of Barcelona; CM receives funding from Instituto de Salud Carlos III, with a Grant for Health Research (PFIS, FI19/00111); NS received compensation for consulting services and speaker honoraria from Genzyme-Sanofi, Almirall, Novartis, Merck and Biogen; MS received speaker honoraria from Genzyme, Novartis and Biogen; IP-V holds a patent for an affordable eye tracking system to measure eye movement in neurological diseases and stock options in Aura Innovative Robotics; YB received speaking honoraria from Biogen, Novartis and Genzyme; AS received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA, Novartis and Roche; SL received compensation for consulting services and speaker honoraria from Biogen Idec, Novartis, TEVA, Genzyme, Sanofi and Merck.</p></sec></ack><fn-group><fn id="s0100" fn-type="supplementary-material"><label>Appendix A</label><p id="p0165">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nicl.2020.102411" id="ir020">https://doi.org/10.1016/j.nicl.2020.102411</ext-link>.</p></fn></fn-group></back></article>